Srdan Verstovsek, M.D., Ph.D. is Chief, Section for myeloproliferative neoplasms (MPNs) in the Leukemia department and Founder/Director of the largest MPN Clinical Research Center worldwide. Dr. Verstovsek’s contributions in MPN have been globally recognized with numerous invitations as an expert speaker/educator/Chair at the most significant national and international conferences (for example ASH, ASCO, and EHA). Dr. Verstovsek has authored more than 600 peer-reviewed original articles and reviews that were published in prestigious journals. Dr. Verstovsek regularly engages at multiple levels with MPN patients’ advocacy groups and societies and publishes the newsletter MPN Focus for patient education.
The MPN team was formed in 2005. At that time, the team included one physician and one research nurse, with only one active MPN-specific clinical protocol. The MPN team has grown exponentially since that time and currently includes more than 8 research nurses, 4 data coordinators and 4 laboratory personnel. Dr. Verstovsek has led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved and cornerstone medication for myelofibrosis until 2019, and second-line treatment for polycythemia vera. Dr. Verstovsek is currently leading pivotal phase 3 trials for several promising myelofibrosis medications.
Elias Jabbour, M.D., Professor, Leukemia department
Prithviraj Bose, M.D., Associate Professor, Leukemia department
Naval Daver, M.D., Associate Professor, Leukemia department
Naveen Pemmaraju, M.D., Associate Professor, Leukemia department
Uday Popat, M.D., Professor, Stem Cell Transplantation department
Carlos Bueso-Ramos, M.D., Ph.D., Professor, Hematopathology department
Myeloproliferative Neoplasms (MPN) Team Members who received the 2020 Waun Ki Hong Award for Excellence in Team Science
"This vibrant and prolific MPN Team has led to exceptional advancements in prognosis, diagnosis and treatment of MPN that have significantly improved patient quality of life and survival through collaborative efforts and discovery, and combined clinical, morphologic, and molecular expertise." - Awards Committee